SC-101 in Subjects With Advanced NECTIN4-Amplified Cancers

Launched by TIANJIN CONJUSTAR BIOLOGICS CO., LTD. · Jul 20, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment called SC-101 for people with advanced cancers that have a specific change in their genes called NECTIN4 amplification. The trial focuses on certain types of breast cancer, including triple-negative breast cancer and hormone receptor-positive breast cancer, especially when the cancer has spread or is hard to treat. The goal is to see how well SC-101 works on its own and to check if it is safe for patients.

To join this study, participants need to be between 18 and 75 years old, have a good overall health status, and have this specific NECTIN4 gene change in their cancer. They should also be expected to live at least three more months and be able to follow the study’s procedures, including using birth control if they can have children. People with unstable brain tumors or serious heart and blood vessel problems won’t be eligible. The trial is not recruiting yet, but those who participate can expect close monitoring of their health and how the treatment affects their cancer over time.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age between 18 and 75 years (inclusive), regardless of gender.
• • ECOG performance status of 0-1.
• • Expected survival of more than 3 months, as assessed by the investigator.
• • Fertile participants must agree to use contraception.
• • Able to understand the trial requirements and willing and able to comply with the trial and follow-up procedures.
• • Adequate bone marrow and organ function.
• • NECTIN-4 gene amplification positive.
• Exclusion Criteria:
• • Unstable central nervous system tumors.
• • Adverse reactions from previous anticancer treatments have not recovered to a CTCAE 5.0 grade ≤1.
• • A history of severe cardiovascular or cerebrovascular disease.